Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Anebulo Pharmaceuticals Announces Interim Data For ANEB-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication; Says Lower Doses Of ANEB-001 Reduced The Negative Effects Of Higher Doses Of THC

Lower doses of ANEB-001 reduced the negative effects of higher doses of THC Currently exploring delayed dosing to better understand real-world conditions AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals,

ANEB